Pfizer, Takeda and Alphabet-backed degenerative disease drug developer Cortexyme priced its initial public offering in the middle of its range to raise $75m.

Cortexyme, a US-based Alzheimer’s disease drug developer which counts internet and technology group Alphabet and pharmaceutical firms Pfizer and Takeda, floated yesterday in a $75m initial public offering. The company issued 4.4 million shares on the Nasdaq Global Market priced at $17.00 each, in the middle of the IPO’s $16 to $18 range. Its shares…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.